• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    2/10/26 4:22:59 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email
    dhr-20260205
    False000031361600003136162026-02-052026-02-050000313616us-gaap:CommonStockMember2026-02-052026-02-050000313616dhr:A0.2SeniorNotesDue2026Member2026-02-052026-02-050000313616dhr:A2.1SeniorNotesDue2026Member2026-02-052026-02-050000313616dhr:A1.2SeniorNotesDue2027Member2026-02-052026-02-050000313616dhr:A0.45SeniorNotesDue2028Member2026-02-052026-02-050000313616dhr:A2.5SeniorNotesDue2030Member2026-02-052026-02-050000313616dhr:A0.75SeniorNotesDue2031Member2026-02-052026-02-050000313616dhr:A1.35SeniorNotesDue2039Member2026-02-052026-02-050000313616dhr:A1.8SeniorNotesDue2049Member2026-02-052026-02-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    __________________
    FORM 8-K
    __________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
    Date of report (Date of earliest event reported): February 5, 2026
    __________________
    dhrlogo.jpg
    DANAHER CORPORATION
    (Exact Name of Registrant as Specified in Its Charter)
    __________________
    Delaware001-0808959-1995548
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
    2200 Pennsylvania Avenue, N.W., 20037-1701
    Suite 800W
    Washington,DC
    (Address of Principal Executive Offices) (Zip Code)
    202-828-0850
    (Registrant’s Telephone Number, Including Area Code)
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)
    __________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common stock, $0.01 par valueDHRNew York Stock Exchange
    0.200% Senior Notes due 2026DHR/26New York Stock Exchange
    2.100% Senior Notes due 2026DHR 26New York Stock Exchange
    1.200% Senior Notes due 2027DHR/27New York Stock Exchange
    0.450% Senior Notes due 2028DHR/28New York Stock Exchange
    2.500% Senior Notes due 2030DHR 30New York Stock Exchange
    0.750% Senior Notes due 2031DHR/31New York Stock Exchange
    1.350% Senior Notes due 2039DHR/39New York Stock Exchange
    1.800% Senior Notes due 2049DHR/49New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 



    ITEM 5.02DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
    On February 5, 2026, Jessica L. Mega notified Danaher Corporation’s (“Danaher”) Board of Directors (“Board”) of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega’s decision was not the result of any disagreement with Danaher on any matter relating to Danaher’s operations, policies or practices.

    ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
    (c)Exhibits:
    Exhibit No.  Description
    104 Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    DANAHER CORPORATION
    Date:February 5, 2026By:/s/ James F. O’Reilly
    James F. O’Reilly
    Senior Vice President, Deputy General Counsel and Secretary; Chief Sustainability Officer


    Get the next $DHR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    12/9/2025$265.00Buy
    Goldman
    12/2/2025$270.00Overweight
    Morgan Stanley
    10/8/2025$220.00Buy → Neutral
    Rothschild & Co Redburn
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $DHR
    SEC Filings

    View All

    SEC Form 10-K filed by Danaher Corporation

    10-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/24/26 4:36:41 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Leadership Update

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/17/26 8:08:12 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    2/10/26 4:22:59 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Riley Christopher Paul was granted 6,172 shares and covered exercise/tax liability with 1,115 shares, increasing direct ownership by 33% to 20,400 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:02 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SVP-Chief Legal Officer Leiken Jonathan was granted 2,374 shares, increasing direct ownership by 23% to 12,546 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:26 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Executive Vice President Mcgrew Matthew was granted 5,935 shares, increasing direct ownership by 28% to 26,825 units (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    3/3/26 7:52:22 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Danaher with a new price target

    Goldman initiated coverage of Danaher with a rating of Buy and set a new price target of $265.00

    12/9/25 8:43:56 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Morgan Stanley initiated coverage on Danaher with a new price target

    Morgan Stanley initiated coverage of Danaher with a rating of Overweight and set a new price target of $270.00

    12/2/25 8:25:25 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Danaher from Buy to Neutral and set a new price target of $220.00

    10/8/25 8:23:31 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Danaher Announces Quarterly Dividend

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and

    2/24/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher to Present at TD Cowen Health Care Conference

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Tuesday, March 3, 2025 at 1:50 p.m. ET. The event will be simultaneously webcast and can be accessed on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health

    2/24/26 4:05:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Jonathan Leiken as General Counsel

    WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca

    7/31/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Financials

    Live finance-specific insights

    View All

    Danaher Announces Quarterly Dividend

    WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and

    2/24/26 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Danaher Reports Fourth Quarter and Full Year 2025 Results

    WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025.  All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted. Key Fourth Quarter 2025 Results Net earnings were $1.2 billion, or $1.66 per diluted common share.Non-GAAP adjusted diluted net earnings per common share grew 4.0% to $2.23.Revenues increased 4.5% year-over-year to $6.8 billion and non-GAAP core revenue increased 2.5% year-over-year.Operating cash flow was $2.1 billion and non-GAAP free cash flow was $1.8 billion.Key Full Year 2025 Results Net earni

    1/28/26 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/23 11:16:32 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/22 3:43:35 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

    11/2/21 9:29:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials